US FDA approves Novartis Kesimpta (ofatumumab) for relapsing forms of MS treatment
Ofatumumab was first approved by the FDA in 2009 for the treatment of chronic lymphocytic leukaemia (CLL)
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Ofatumumab
Novartis acquires all remaining rights to GSK’s Ofatumumab
To develop treatments for MS and other autoimmune indications